First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Clinical trial NCT02906163 · UNKNOWN
Trial details
- NCT number
- NCT02906163
- Sponsor
- SciClone Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-01
- Primary completion
- 2019-12-01
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.